Sanara MedTech reports Q3 EPS ($3.40) vs (34c) last year

Reports Q3 revenue $26.3M vs $21.67M last year. “Our surgical team delivered strong sales performance in the third quarter, culminating in net revenue growth of 22% year-over-year,” stated Seth Yon, Sanara’s President and Chief Executive Officer. “Our net revenue growth was fueled by a 24% increase in sales of our surgical soft tissue products, including CellerateRX Surgical and BIASURGE. This performance reflects the success of our commercial strategy to develop relationships with independent distributors, expand into new healthcare facilities, and penetrate existing facilities by adding new surgeon users. In addition, we achieved notable year-over-year improvements in our profitability profile, with a $1.0 million improvement in net income from continuing operations and a $2.3 million improvement in Adjusted EBITDA, on net revenue growth of $4.7 million year-over-year.”